Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Savient Pharmaceuticals Neurologic AIDS Research Consortium (NARC) |
---|---|
Information provided by: | Savient Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00286377 |
This is a double-blind, placebo-controlled, parallel groups study to determine whether prosptide is effective in relieving pain in patients who have sensory neuropathic pain related to their HIV infection or the drugs used to treat it.
Condition | Intervention | Phase |
---|---|---|
HIV Peripheral Nervous System Disorders |
Drug: prosaptide |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of Prosaptide Over 6 Weeks of Treatment for the Relief of Neuropathic Pain Associated With HIV-1 |
Estimated Enrollment: | 350 |
Study Start Date: | September 2003 |
Estimated Study Completion Date: | December 2004 |
Sensory neruopathies are the most frequent neurological complicaton of HIV infection and its treatmet with antiretrovirals. To date, there are few effective treatments, and all are symptomatic treatments for pain. Management typically involves the intiation and adjustment of pain-modifying therapies, and the adjustment or discontinuation of potentially neurotoxic antiretrovirals, thereby limiting the choice of HAART regimens.
In precinical animal models,prosaptide has been shown to be efficacious in the treatment of neuropathic pain caused by a variety of different mechanisms.
Hypothesis: Prosaptide will improve neuropathic pain in HIV-associated sensory neuroathies,and will be safe and well tolerated in subjects.
Comparisons: 4, 8, or 16 mg prosaptide vs. placebo
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria: - Ages 18 years and older
Study ID Numbers: | C0603, NARC # 009 |
Study First Received: | June 30, 2005 |
Last Updated: | February 2, 2006 |
ClinicalTrials.gov Identifier: | NCT00286377 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Neuromuscular Diseases HIV Seropositivity HIV Infections |
Peripheral Nervous System Diseases Acquired Immunodeficiency Syndrome Pain |
Neuromuscular Diseases Peripheral Nervous System Diseases Nervous System Diseases |